Biomolecular predictors of urothelial cancer behavior and treatment outcomes

Current Urology Reports

Volumn 13, Issue 2, 2012, Pages 122-135

  Rink, Michael ^a,b   Cha, Eugene K ^a   Green, David ^a   Hansen, Jens ^b,c   Robinson, Brian D ^a   Lotan, Yair ^d   Sagalowsky, Arthur I ^d   Chun, Felix X ^b   Karakiewicz, Pierre I ^c   Fisch, Margit ^b   Scherr, Douglas S ^a   Shariat, Shahrokh F ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Biomarker; Bladder cancer; Molecular marker; Prediction; Prognosis; Survival; Urothelial carcinoma

Indexed keywords

ANDROGEN RECEPTOR; BCG VACCINE; CASPASE 3; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P27; RETINOBLASTOMA PROTEIN; SURVIVIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VINBLASTINE;

ADVANCED CANCER; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CIRCULATING TUMOR CELL; CYSTECTOMY; GENE; HUMAN; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; P21 GENE; P53 GENE; PREDICTIVE VALUE; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REVIEW; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE;

CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84860770688     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-012-0237-1     Document Type: Review

References (96)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300. doi:10.3322/caac.20073.
2. Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 2006;176(4 Pt 1):1354-61. discussion 61-2.
3. Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res. 2006;12(22):6663-76. (Pubitemid 44876834)
4. Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol. 2006;24(24):3967-72. (Pubitemid 46630745)
5. Rink M, Shariat SF. Can we apply nomograms derived in the United States to European patients? Yes, We Can! Eur Urol. 2011 (Epub ahead of print).
6. Barbieri CE, Lotan Y, Lee RK, Sonpavde G, Karakiewicz PI, Robinson B, et al. Tissue-based molecular markers for bladder cancer. Minerva Urol Nefrol. 2010;62(3):241-58.
7. Matsushita K, Cha EK, Matsumoto K, Baba S, Chromecki TF, Fajkovic H et al. Immunohistochemical biomarkers for bladder cancer prognosis. Int J Urol. 2011(Epub ahead of print).
8. Shariat SF, Lotan Y, Vickers A, Karakiewicz PI, Schmitz-Dräger BJ, Goebell PJ, et al. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol. 2010;28(4):389-400. doi:10.1016/j.urolonc.2010.02. 011.
9. Kim YK, Kim WJ. Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol. 2009;16(1):17-22. doi:10.1111/ j.1442-2042.2008. 02143.x.
10. Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008;112(2):315-25. doi:10.1002/cncr.23162.
11. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol. 2008;18(1):1-8. doi:10.1097/ MOU.0b013e3282f1c5c1. (Pubitemid 350307522)
12. Shariat SF, Tilki D. Bladder cancer: nomogram aids clinical decision making after radical cystectomy. Nat Rev Urol. 2010;7 (4):182-4.
13. Vrooman OP, Witjes JA. Molecular markers for detection, surveillance and prognostication of bladder cancer. Int J Urol. 2009;16 (3):234-43. doi:10.1111/j.1442-2042.2008.02225.x.
14. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307-10. doi:10.1038/35042675.
15. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331(19):1259-64. (Pubitemid 24333190)
16. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res. 1998;4(4):829-34. (Pubitemid 28183382)
17. Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22(6):1014-24. doi:10.1200/jco.2004.03.118. (Pubitemid 41095033)
18. Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst. 1998;90 (14):1072-9. (Pubitemid 28350272)
19. Dalbagni G, Presti J, Reuter V, Fair WR, Cordon-Cardo C. Genetic alterations in bladder cancer. Lancet. 1993;342(8869):469-71. (Pubitemid 23240312)
20. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res. 1994;54 (2):531-8. (Pubitemid 24053197)
21. Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol. 2004;22(6):1007-13. doi:10.1200/jco.2004.05.174. (Pubitemid 41095032)
22. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 2005;6(9):678-86. doi:10.1016/s1470-2045(05)70315-6. (Pubitemid 41222758)
23. Shariat SF, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, et al. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol. 2009;182(3):907-13. doi:10.1016/j.juro.2009.05.024.
24. Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol. 2007;20 (4):445-59. doi:10.1038/modpathol. 3800757. (Pubitemid 46482368)
25. Shariat SF, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ, et al. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010;105(4):489-95. doi:10.1111/j.1464-410X.2009.08742.x.
26. •• Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010;183(1):68-75. doi:10.1016/j.juro.2009.08.115. This study demonstrates the importance of using a combination of molecular markers for molecular staging, prognostication, and prediction of response to therapy. While status of individual molecular cell-cycle markers did not add sufficient value to outcome prediction in patients with advanced UCB, a combination of four markers was able to significantly improve prognostications.
27. Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol. 2009;182(1):78-84; discussion doi:10.1016/j.juro.2009.02.125.
28. • Goebell PJ, Groshen SG, Schmitz-Dräger BJ, (ISBC) IS-IoBC. p53 immunohistochemistry in bladder cancer-a new approach to an old question. Urol Oncol. 2010;28(4):377-88. doi:10.1016/j.urolonc.2010.03.021. This large study comprising 3,421 patients demonstrates the value of p53 immunohistochemistry in prognostication of UCB >pT1. The results of this trial demonstrate the relevance of sufficient study size, provide a basis to define suitable patient populations, and allow an estimation of an adequate size of study cohorts for prospective trials.
29. Dalbagni G, Parekh DJ, Ben-Porat L, Potenzoni M, Herr HW, Reuter VE. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int. 2007;99 (2):281-5. doi:10.1111/j.1464-410X. 2006.06624.x. (Pubitemid 46103104)
30. Esuvaranathan K, Chiong E, Thamboo TP, Chan YH, Kamaraj R, Mahendran R, et al. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer. 2007;109(6):1097-105. doi:10.1002/ cncr.22503. (Pubitemid 46435388)
31. Moonen PM, van Balken-Ory B, Kiemeney LA, Schalken JA, Witjes JA. Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J Urol. 2007;177(1):80-3. doi:10.1016/j.juro.2006.08.110. (Pubitemid 44879442)
32. Cormio L, Tolve I, Annese P, Saracino A, Zamparese R, Sanguedolce F, et al. Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer. Anticancer Res. 2009;29 (10):4201-4.
33. Oh JJ, Ji SH, Choi DK, Gong IH, Kim TH, Park DS. A six-week course of bacillus Calmette-Guerin prophylaxis is insufficient to prevent tumor recurrence in nonmuscle invasive bladder cancer with strong-positive expression of p53. Oncology. 2010;79(5- 6):440-6.
34. • Park J, Song C, Shin E, Hong JH, Kim CS, Ahn H. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? Urol Oncol. 2011. This is one of only few studies failing to show an influence of seven different biomarkers on prognostication in 61 pT1G3 UCB patients with a primary BCG treatment. This study is an important example of the difficulties in evaluating biomarkers in UCB.
35. •• Stadler WM, Lerner SP, Groshen S, Stein JP, Shi SR, Raghavan D et al. Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status. J Clin Oncol. 2011. This is the first study reporting a prospective randomized controlled trial assessing the impact of p53 on outcomes of pT1/T2/N0M0 UCB treated with adjuvant chemotherapy. The study demonstrated no difference in disease outcome or benefit of chemotherapy according to the biomarker status.
36. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res. 2006;12(24):7369-73. (Pubitemid 46095410)
37. •• Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst. 2009;101(2):114-9. doi:10.1093/jnci/ djn451. In this large study of 713 patients treated with RC, Ki-67 labeling index was independently associated with aggressive pathological features and worse disease outcome. This marker holds the potential for a better patient stratification for perioperative chemotherapy.
38. Behnsawy HM, Miyake H, Abdalla MA, Sayed MA, Ahmed AE, Fujisawa M. Expression of cell cycle-associated proteins in nonmuscle- invasive bladder cancer: Correlation with intravesical recurrence following transurethral resection. Urol Oncol. 2009.
39. Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol. 2008;26(1):59-65. doi:10.1007/s00345-007-0219-y.
40. Arai M, Sasaki A, Saito N, Nakazato Y. Immunohistochemical analysis of cleaved caspase-3 detects high level of apoptosis frequently in diffuse large B-cell lymphomas of the central nervous system. Pathol Int. 2005;55(3):122-9. doi:10.1111/j.1440- 1827.2005.01808.x. (Pubitemid 40477223)
41. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 2007;8(2):128-36. doi:10.1016/S1470- 2045(07)70002-5. (Pubitemid 46158371)
42. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22(53):8581-9. doi:10.1038/ sj.onc.1207113. (Pubitemid 38019195)
43. Schultz IJ, Kiemeney LA, Karthaus HF, Witjes JA, Willems JL, Swinkels DW, et al. Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin Chem. 2004;50(8):1425-8. doi:10.1373/clinchem.2004.032003. (Pubitemid 38970655)
44. Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC, et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol. 2004;171 (2 Pt 1):626-30. doi:10.1097/01.ju.0000107826.78479.90. (Pubitemid 38090444)
45. Smith SD,Wheeler MA, Plescia J, Colberg JW,Weiss RM, Alterieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA. 2001;285(3):324-8. (Pubitemid 32095036)
46. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer. 2007;109 (6):1106-13. doi:10.1002/cncr. 22521. (Pubitemid 46435389)
47. •• Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res. 2009;15(22):7012-9. doi:10.1158/1078-0432.ccr-08-2554. This large external validation study demonstrates the value of survivin expression for an improved prediction of cancer recurrence and survival in patients with pT1-3N0M0 UCB.
48. Salz W, Eisenberg D, Plescia J, Garlick DS, Weiss RM, Wu XR, et al. A survivin gene signature predicts aggressive tumor behavior. Cancer Res. 2005;65(9):3531-4. doi:10.1158/0008- 5472.can-04-4284. (Pubitemid 40616325)
49. Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol. 2010;183(5):1744-50. doi:10.1016/j.juro.2010. 01.018.
50. Das K, Zhao Y, Sugiono M, Lau W, Tan PH, Cheng C. Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder. Urol Oncol. 2007;25 (4):317-21. (Pubitemid 47031003)
51. Herrmann E, Eltze E, Bierer S, Kopke T, Gorge T, Neumann J, et al. VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival. Anticancer Res. 2007;27(5A):3127-33. (Pubitemid 47607535)
52. Miyata Y, Kanda S, Ohba K, Nomata K, Hayashida Y, Eguchi J, et al. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. Clin Cancer Res. 2006;12(3 Pt 1):800-6. doi:10.1158/1078-0432.ccr-05-1284. (Pubitemid 43259860)
53. Zu X, Tang Z, Li Y, Gao N, Ding J, Qi L. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int. 2006;98 (5):1090-3. doi:10.1111/j.1464-410X. 2006.06446.x. (Pubitemid 44536464)
54. Elfiky AA, Rosenberg JE. Targeting angiogenesis in bladder cancer. Curr Oncol Rep. 2009;11(3):244-9.
55. Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol. 2009;4:251-85.
56. Knowles MA. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol. 2007;25 (6):581-93. doi:10.1007/s00345-007-0213-4.
57. van Rhijn BW, Zuiverloon TC, Vis AN, Radvanyi F, van Leenders GJ, Ooms BC, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol. 2010;58(3):433-41.
58. Fajkovic H, Halpern JA, Cha EK, Bahadori A, Chromecki TF, Karakiewicz PI, et al. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol. 2011;29(4):457-63.
59. Kaufmann M, Pusztai L. Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel. Cancer. 2011;117(8):1575-82.
60. Jimenez RE, Hussain M, Bianco Jr FJ, Vaishampayan U, Tabazcka P, Sakr WA, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res. 2001;7(8):2440-7. (Pubitemid 32751647)
61. Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, Brown GA, et al. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol. 2008;179 (1):353-8. doi:10.1016/j.juro.2007. 08.087. (Pubitemid 350216717)
62. Kruger S, Weitsch G, Buttner H, Matthiensen A, Bohmer T, Marquardt T, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer. 2002;102(5):514-8. doi:10.1002/ijc.10731. (Pubitemid 35316007)
63. Lae M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol. 2010;21 (4):815-9.
64. •• Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol. 2011;60(2):350-7. According to the results of this study, a targeted anti-HER2 therapy might have a greater potential in patients with metastatic disease than in patients with localized UCB. Furthermore, it is important to notice that HER2 expression is higher in metastatic sites and, therefore, analysis of primary tumor specimens might offer only an invalid picture of HER2 status.
65. Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI, et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int. 2010;106(8):1216-22. doi:10.1111/j.1464-410X.2009. 09190.x.
66. Boorjian S, Ugras S, Mongan NP, Gudas LJ, You X, Tickoo SK, et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology. 2004;64(2):383-8. doi:10.1016/j.urology.2004.03. 025. (Pubitemid 39092488)
67. • Tuygun C, Kankaya D, Imamoglu A, Sertcelik A, Zengin K, Oktay M et al. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol. 2011;29(1):43-51. doi:10.1016/j.urolonc.2009.01.033. Only few studies investigated the value of sex hormonal receptors with respect to gender differences in UCB outcomes. This study investigated altered marker level of the androgen and estrogen-β receptor.
68. Mir C, Shariat SF, van der Kwast TH, Ashfaq R, Lotan Y, Evans A, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int. 2011;108(1):24-30.
69. Bolenz C, Lotan Y, Ashfaq R, Shariat SF. Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. Eur Urol. 2009;56(6):1093-5. doi:10.1016/j.eururo.2009.06.032.
70. Shen SS, Smith CL, Hsieh JT, Yu J, Kim IY, Jian W, et al. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer. 2006;106 (12):2610-6. doi:10.1002/cncr.21945.
71. Shariat SF, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, et al. Combination of cell cycle regulating bio-markers improves prognosis in patients with organ-confined urothelial carcinoma at radical cystectomy. J Urol. 2008;179(4):578.
72. Shariat SF, Kim J, Nguyen C, Wheeler TM, Lerner SP, Slawin KM. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology. 2003;61(2):359-64. (Pubitemid 36206533)
73. Byrne RR, Shariat SF, Brown R, Kattan MW, Morton Jr RA, Wheeler TM, et al. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol. 2001;165(5):1473-9. (Pubitemid 32410217)
74. Shariat SF, Monoski MA, Andrews B, Wheeler TM, Lerner SP, Slawin KM. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology. 2003;61(5):1053-8. (Pubitemid 36547769)
75. Andrews B, Shariat SF, Kim J-H, Wheeler TM, Slawin KM, Lerner SP. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol. 2002;167(3):1475-81. (Pubitemid 34132135)
76. Kim JH, Shariat SF, Kim IY, Menesses-Diaz A, Tokunaga H, Wheeler TM, et al. Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder. Cancer. 2001;92(6):1475-83. (Pubitemid 32947832)
77. Shariat SF, Kim JH, Andrews B, Kattan MW, Wheeler TM, Kim IY, et al. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001;92(12):2985-92. (Pubitemid 33136192)
78. Castillejo A, Rothman N, Murta-Nascimento C, Malats N, Garcia- Closas M, Gomez-Martinez A, et al. TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. Int J Cancer. 2009;124(3):608-13.
79. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999;274(31):21491-4. (Pubitemid 129519680)
80. Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, et al.Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol. 1998;161(12):6845-52. (Pubitemid 28562229)
81. Ito T-K, Ishii G, Saito S, Yano K, Hoshino A, Suzuki T, et al. Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells. Blood. 2009;113(10):2363-9. doi:10.1182/blood-2008-08-172742.
82. Guan K-P, Ye H-Y, Yan Z, Wang Y, Hou S-K. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology. 2003;61(4):719-23. (Pubitemid 36384961)
83. Vasala K, Pääkkö P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology. 2003;62(5):952-7. (Pubitemid 37421256)
84. •• Svatek RS, Shah JB, Xing J, Chang D, Lin J, Mcconkey DJ et al. A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancerrelated death among patients with bladder cancer. Cancer. 2010;116(19):4513-9. doi:10.1002/cncr.25401. This study suggests that MMP-7 can help stratify patients for neoadjuvant or adjuvant treatment. Plasma levels of MMP-7 were significantly associated with cancer-specific survival.
85. Szarvas T, Becker M, Vom Dorp F, Gethmann C, Tötsch M, Bánkfalvi A, et al. Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci. 2010;101(5):1300-8. doi:10.1111/j.1349-7006.2010.01506.x.
86. Szarvas T, Singer BB, Becker M, Vom Dorp F, Jager T, Szendroi A, et al. Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer. BJU Int. 2011;107(7):1069-73.
87. Szarvas T, Jager T, Becker M, Tschirdewahn S, Niedworok C, Kovalszky I, et al. Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer. Pathol Oncol Res. 2011;17(2):325-32.
88. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781-91. (Pubitemid 39095313)
89. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302-9.
90. Msaouel P, Koutsilieris M. Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. BMC Cancer. 2011;11(1):336.
91. Nezos A, Msaouel P, Pissimissis N, Lembessis P, Sourla A, Armakolas A, et al. Methods of detection of circulating melanoma cells: a comparative overview. Cancer Treat Rev. 2010;37 (4):284-90.
92. Gallagher DJ, Milowsky MI, Ishill N, Trout A, Boyle MG, Riches J, et al. Detection of circulating tumor cells in patients with urothelial cancer. Ann Oncol. 2009;20(2):305-8.
93. Gradilone A, Petracca A, Nicolazzo C, Gianni W, Cortesi E, Naso G, et al. Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int. 2010;106 (5):710-5.
94. Guzzo TJ, McNeil BK, Bivalacqua TJ, Elliott DJ, Sokoll LJ, Schoenberg MP. The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy. Urol Oncol. 2009.
95. • Rink M, Chun FK, Minner S, Friedrich M, Mauermann O, Heinzer H et al. Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int. 2011;107(10):1668-75. This is the first study demonstrating an association of immunomagnetically captured CTC in the peripheral blood of patients with nonmetastatic UCB and worse cancer-specific outcomes.
96. Mitra AP, Lin H, Datar RH, Cote RJ. Molecular biology of bladder cancer: prognostic and clinical implications. Clin Genitourin Cancer. 2006;5(1):67-77.